PPLPHARMA vs WANBURY: Stock Comparison
PIRAMAL PHARMA is the larger company by market capitalisation. PIRAMAL PHARMA shows faster revenue growth and lower leverage, while WANBURY shows a higher ROE, a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
PPLPHARMA leads 3; WANBURY leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | PPLPHARMA | WANBURY |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | PPLPHARMA | WANBURY |
|---|---|---|
| Live Price | ₹211.35 | ₹239.35 |
| Day Change | -0.54% | -0.87% |
| Volume | 34.09 L | 59,568 |
| 52-Week High | ₹231.93 | ₹358.85 |
| 52-Week Low | ₹132.3 | ₹161.5 |
| Distance from 52W High | -8.87% | -33.3% |
Valuation
| Metric | PPLPHARMA | WANBURY |
|---|---|---|
| Market Cap | ₹28,211 Cr | ₹832 Cr |
| P/E Ratio | 0x | 0x |
| P/B Ratio | 3.45x | 0x |
| EPS | ₹0.85 | ₹0.93 |
| Book Value | ₹61.31 | ₹41.34 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | PPLPHARMA | WANBURY |
|---|---|---|
| Revenue Growth (TTM YoY) | -0.1% | -19.2% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | -50.44% | 0.61% |
| Qtr Profit Growth | 263.54% | -85.06% |
Profitability & Leverage
| Metric | PPLPHARMA | WANBURY |
|---|---|---|
| ROE | -3.99% | 45.78% |
| ROCE | 0.86% | 25.06% |
| Net Margin | -3.68% | 10.17% |
| Operating Margin | 1.21% | 13.81% |
| Debt to Equity | 0.67x | 1.49x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | PPLPHARMA | WANBURY |
|---|---|---|
| Promoter Holding | 34.8%▼ 0.06 pp | 34.36% |
| FII Holding | 12.52%▼ 17.66 pp | 0.89%▲ 0.3 pp |
| DII Holding | 14.57%▼ 1.04 pp | 0.06%▲ 0.06 pp |
| Public Holding | 37.63%▲ 18.62 pp | 56.03%▼ 0.36 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: PIRAMAL PHARMA and WANBURY.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.